- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02798419
Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts
August 15, 2016 updated by: Dr. Reddys Laboratories, SA
DFD05 vs. Active01 in the treatment of common warts
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Hot Springs, Arkansas, United States, 71913
- Investigation Site #1
-
-
California
-
Fremont, California, United States, 94538
- Investigational Site #4
-
Sacramento, California, United States, 95821
- Investigational Site #11
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80904
- Investigational Site #2
-
-
Florida
-
Tampa, Florida, United States, 33609
- Investigational Site #12
-
-
Georgia
-
Marietta, Georgia, United States, 30060
- Investigational Site #9
-
-
Illinois
-
Arlington Hts, Illinois, United States, 60005
- Investigational Site #3
-
-
Louisiana
-
Crowley, Louisiana, United States, 70526
- Investigational Site #10
-
-
Minnesota
-
Fridley, Minnesota, United States, 55432
- Investigational Site #8
-
-
Rhode Island
-
Johnston, Rhode Island, United States, 02919
- Investigational Site #6
-
-
Texas
-
Austin, Texas, United States, 78759
- Investigational Site #5
-
College Station, Texas, United States, 77845
- Investigational Site #7
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects, any gender or race, must be in good general health as determined by the Investigator with a clinical diagnosis of common warts.
- Subjects must have at least 1 visible, discrete, common wart with at least a 3 mm longitudinal diameter on the hands, feet (excluding soles) and palms (in that order of priority).
- The warts must have been present for at least the past 12 weeks, but not more than 3 years
- Subjects must agree to only use the study products and to not use any other wart-removing product (prescription, OTC or occlusion) during the course of the study.
- Subjects must be free of any systemic or dermatologic disorder, which in the opinion of the Investigator, will interfere with the study results.
- Female subjects of childbearing potential must agree to use contraception during the study. All women of childbearing potential must have a negative urine pregnancy test at Screening and Baseline and at 4, 8 & 12 weeks visits.
- Subjects are physically able to apply study product to all affected areas or can obtain help.
Exclusion Criteria:
- Women who are pregnant or nursing or planning to become pregnant during the study.
- Subjects who have been treated for warts within the 30 days prior to the Baseline Visit (e.g. salicylic acid, azelaic acid, cryotherapy).
- Subjects who have participated in a trial involving any investigational product in the 30 days prior to the Baseline Visit.
- Subjects with chronic or active liver disease, renal impairment, cutaneous or systemic lupus erythematosus, an autoimmune disorder, immunosuppression, or any other disease or medical condition that would interfere with the study or place the subject at unacceptable risk, as determined by the investigator.
- Subjects on immunosuppressive agents that would impact their immune response e.g. cyclosporine, mycophenolate mofetil, azathioprine, etc.
- Subjects who use or have used local/systemic steroids or any other immunosuppressive medication within the 30 days prior to the Baseline Visit.
- Subjects who use or have used systemic or topical retinoids within the 30 days prior to the Baseline Visit.
- Subjects who are unable to comply with study requirements.
- Subjects with other skin diseases like molluscum contagiosum that may confound the evaluation of common warts.
- Subjects who have received treatment for any type of cancer within 5 years of the Baseline Visit, except skin cancer and cervical cancer (in situ) are allowed if at least 1 year before the Baseline Visit.
- Subjects unable to comply with study requirements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: DFD05 Cream
|
|
ACTIVE_COMPARATOR: Active01 Cream
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of subjects categorized as treatment responders (defined as having at least 91% reduction in surface area, averaged across all target warts)
Time Frame: Visit 5 (week 12)
|
Visit 5 (week 12)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (ACTUAL)
May 1, 2016
Study Completion (ACTUAL)
August 1, 2016
Study Registration Dates
First Submitted
June 9, 2016
First Submitted That Met QC Criteria
June 13, 2016
First Posted (ESTIMATE)
June 14, 2016
Study Record Updates
Last Update Posted (ESTIMATE)
August 16, 2016
Last Update Submitted That Met QC Criteria
August 15, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DFD05-CD-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Common Warts
-
Maruho Co., Ltd.CompletedCutaneous Common WartsUnited States
-
Maruho Co., Ltd.CompletedCutaneous Common WartsUnited States
-
Karo Pharma ABCompletedPlantar Wart | Common WartPoland
-
Nielsen BioSciences, Inc.Recruiting
-
Aclaris Therapeutics, Inc.CompletedCommon WartUnited States
-
Aclaris Therapeutics, Inc.Completed
-
Aclaris Therapeutics, Inc.Completed
-
Aclaris Therapeutics, Inc.Completed
-
Assiut UniversityUnknown
-
Aclaris Therapeutics, Inc.Completed
Clinical Trials on DFD05 Cream
-
University of North Carolina, CharlotteTeva Branded Pharmaceutical Products R&D, Inc.CompletedMultiple SclerosisUnited States
-
Incyte CorporationCompletedCutaneous Lichen PlanusUnited States, Canada
-
Incyte CorporationRecruitingPrurigoUnited States, Spain, France, Poland, Germany, Belgium, Netherlands, Argentina, Italy, Canada, Chile, Brazil
-
Edesa Biotech Inc.JSS Medical Research Inc.Active, not recruitingAllergic Contact DermatitisUnited States, Canada
-
LEO PharmaCompletedChronic Hand EczemaUnited States, Germany, Denmark
-
LEO PharmaCompletedHealthy VolunteersGermany
-
Incyte CorporationCompletedHidradenitis SuppurativaUnited States, Canada
-
Incyte CorporationCompletedLichen SclerosusUnited States, Canada
-
LEO PharmaTerminatedDiscoid Lupus ErythematosusUnited States, France, Germany, Denmark
-
Incyte CorporationRecruitingPrurigo NodularisSpain, Korea, Republic of, United States, Poland, Italy, Austria, Germany, Canada, Switzerland, Australia, France, Denmark, Bulgaria